138 related articles for article (PubMed ID: 38206506)
1. ASO Author Reflections: Neoadjuvant Chemotherapy Does not Increase Postoperative Complications Compared with Upfront Surgery in Gastric Adenocarcinoma: A Population-Based, Nationwide Study in Finland.
Emilia P; Helminen O; Kauppila JH;
Ann Surg Oncol; 2024 Apr; 31(4):2711-2712. PubMed ID: 38206506
[No Abstract] [Full Text] [Related]
2. Postoperative Complications After Neoadjuvant Chemotherapy Versus Upfront Surgery in Gastric Adenocarcinoma: A Population-Based Nationwide Study in Finland.
Putila E; Helminen O; Helmiö M; Huhta H; Jalkanen A; Kallio R; Koivukangas V; Kokkola A; Laine S; Lietzen E; Louhimo J; Meriläinen S; Pohjanen VM; Rantanen T; Junttila A; Ristimäki A; Räsänen JV; Saarnio J; Sihvo E; Toikkanen V; Tyrväinen T; Valtola A; Kauppila JH;
Ann Surg Oncol; 2024 Apr; 31(4):2689-2698. PubMed ID: 38153640
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract][Full Text] [Related]
4. The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial.
Hashemzadeh S; Pourzand A; Somi MH; Zarrintan S; Javad-Rashid R; Esfahani A
Int J Surg; 2014 Oct; 12(10):1061-9. PubMed ID: 25157992
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer-Standard of Care or Still Worth Debating?
Chawla A; Wang J
Ann Surg Oncol; 2020 Apr; 27(4):1201-1202. PubMed ID: 31848817
[No Abstract] [Full Text] [Related]
6. Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Nowak K; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
Eur J Surg Oncol; 2017 Aug; 43(8):1550-1558. PubMed ID: 28551325
[TBL] [Abstract][Full Text] [Related]
7. ASO Author Reflections: Future Prospects of Neoadjuvant Chemotherapy for Gastric Cancer.
Kano M; Matsubara H
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):721-722. PubMed ID: 31797227
[No Abstract] [Full Text] [Related]
8. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.
Marcus SG; Cohen D; Lin K; Wong K; Thompson S; Rothberger A; Potmesil M; Hiotis S; Newman E
J Gastrointest Surg; 2003 Dec; 7(8):1015-22; discussion 1023. PubMed ID: 14675711
[TBL] [Abstract][Full Text] [Related]
9. Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer.
Téoule P; Trojan J; Bechstein W; Woeste G
Dig Surg; 2015; 32(4):229-37. PubMed ID: 25966823
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.
Schuhmacher C; Gretschel S; Lordick F; Reichardt P; Hohenberger W; Eisenberger CF; Haag C; Mauer ME; Hasan B; Welch J; Ott K; Hoelscher A; Schneider PM; Bechstein W; Wilke H; Lutz MP; Nordlinger B; Van Cutsem E; Siewert JR; Schlag PM
J Clin Oncol; 2010 Dec; 28(35):5210-8. PubMed ID: 21060024
[TBL] [Abstract][Full Text] [Related]
11. ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.
Adam MA; Paniccia A
Ann Surg Oncol; 2021 Jul; 28(7):3808-3809. PubMed ID: 33475885
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: The Prognostic Value of Pathologic Complete Response After Neoadjuvant Chemotherapy in Gastric Cancer.
Lin C; Liu F
Ann Surg Oncol; 2023 Sep; 30(9):5543. PubMed ID: 37355520
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: Number of Examined Lymph Nodes in Gastric Cancer Resection Following Neoadjuvant Chemotherapy.
Shannon AB; Karakousis GC
Ann Surg Oncol; 2022 Feb; 29(2):1254-1255. PubMed ID: 34609647
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Gastrectomy Within 30 Days After Neoadjuvant Chemotherapy is Associated with the Highest Rate of Major Pathologic Response in Advanced Gastric Cancer.
Reinsoo A; Bausys A; Ümarik T; Strupas K
Ann Surg Oncol; 2021 Aug; 28(8):4456-4457. PubMed ID: 33417117
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancreatic Adenocarcinoma.
O'Shea AE; Carpenter EL; Nelson DW; Vreeland TJ
Ann Surg Oncol; 2022 Sep; 29(9):6029-6030. PubMed ID: 35583695
[No Abstract] [Full Text] [Related]
16. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
[No Abstract] [Full Text] [Related]
17. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
18. ASO Author Reflection: Adjuvant Chemotherapy After Neoadjuvant Chemotherapy in Pancreatic Adenocarcinoma Does Not Lead to Improved Survival in All Patients.
Olecki EJ; Gusani NJ
Ann Surg Oncol; 2021 Jun; 28(6):3123. PubMed ID: 33616769
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Do Advances in Neoadjuvant Therapy Influence How We Surgically Manage the Regional Lymphatics in Gastric Cancer?
Allen CJ; Badgwell BD
Ann Surg Oncol; 2020 Feb; 27(2):543-544. PubMed ID: 31650303
[No Abstract] [Full Text] [Related]
20. Population-based nationwide incidence of complications after gastrectomy for gastric adenocarcinoma in Finland.
Putila E; Helminen O; Helmiö M; Huhta H; Jalkanen A; Kallio R; Koivukangas V; Kokkola A; Laine S; Lietzen E; Louhimo J; Meriläinen S; Pohjanen VM; Rantanen T; Ristimäki A; Räsänen JV; Saarnio J; Sihvo E; Toikkanen V; Tyrväinen T; Valtola A; Kauppila JH
BJS Open; 2023 Sep; 7(5):. PubMed ID: 37864576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
